Want to see XBIO full AI Analyst Report?
Top Page
Xenetic Biosciences
(NASDAQ:XBIO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-60.73% Downside)
Action:Reiterated
Date:10/20/26
The score is primarily weighed down by weak financial performance (ongoing losses, negative cash flow, and declining equity despite no debt) and bearish technicals (below key moving averages with negative MACD). The pending acquisition is a constructive catalyst but is offset by dilution/control and execution risks, while valuation is constrained by losses and the absence of a dividend.
Positive Factors
Revenue growth and gross margin
Strong top-line expansion and high reported gross margins indicate that XBIO is generating meaningful revenue growth with favorable direct economics. If sustained, this combination can support reinvestment in development programs and improve operating leverage as the business scales.
Negative Factors
Persistent operating losses
Deeply negative profitability shows that current revenue is not yet sufficient to cover operating costs, leaving earnings dependent on future program progress and commercialization. Until scale or product economics improve, the company remains exposed to prolonged losses and uncertain earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and gross margin
Strong top-line expansion and high reported gross margins indicate that XBIO is generating meaningful revenue growth with favorable direct economics. If sustained, this combination can support reinvestment in development programs and improve operating leverage as the business scales.
Read all positive factors
Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.33M
Dividend YieldN/A
Average Volume (3M)118.90K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth33.30%
EPS Growth40.59%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.19
Shares Outstanding2,343,181
10 Day Avg. Volume19,516
30 Day Avg. Volume118,901
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Xenetic Biosciences Business Overview & Revenue Model
Company Description
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack...
Xenetic Biosciences Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.26M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Gross Profit | 3.26M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| EBITDA | -2.48M | -2.68M | -3.81M | -4.13M | -6.53M | -5.61M |
| Net Income | -2.48M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
Balance Sheet | ||||||
| Total Assets | 6.97M | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Cash, Cash Equivalents and Short-Term Investments | 6.47M | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.04K |
| Total Liabilities | 894.98K | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Stockholders Equity | 6.07M | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
Cash Flow | ||||||
| Free Cash Flow | -2.31M | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M |
| Operating Cash Flow | -2.31M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 |
| Financing Cash Flow | 4.00M | 4.00M | 0.00 | 0.00 | 0.00 | 11.45M |
Xenetic Biosciences Technical Analysis
Negative
3.82
Price Trends
2.95
Negative
2.93
Negative
2.85
Negative
Market Momentum
-0.28
Negative
34.09
Neutral
22.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 3.82 is above the 20-day moving average (MA) of 2.08, above the 50-day MA of 2.95, and above the 200-day MA of 2.85, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 34.09 is Neutral, neither overbought nor oversold. The STOCH value of 22.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.
Xenetic Biosciences Risk Analysis
Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xenetic Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
XBIO
Xenetic Biosciences
1.85
-1.90
-50.67%
ERNA
Eterna Therapeutics
1.94
-27.81
-93.49%
APRE
Aprea Therapeutics
0.45
-0.89
-66.49%
HCWB
HCW Biologics
1.10
-22.00
-95.24%
Xenetic Biosciences Corporate Events
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Xenetic Updates Investors on Santersus Share Exchange Plans
Neutral
Sep 23, 2026
On September 23, 2026, Xenetic Biosciences released an updated investor presentation tied to its pending share exchange transaction with Swiss-based Santersus AG, a deal first announced on September 16, 2026. The company also confirmed it will fil...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Xenetic Biosciences to Acquire Santersus AG in Merger
Positive
Sep 16, 2026
On September 14, 2026, Xenetic Biosciences agreed to acquire all outstanding shares of Swiss medical device group Santersus AG via an all-stock share exchange that will make Santersus a wholly owned subsidiary, with its investors owning roughly 85...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.